Balyasny Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Balyasny Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.81M	Sell	6,300 -800	-11%	-$373K	﹤0.01%	1626
2025 Q4	$3.22M	Buy	+7,100	New	+$3.06M	﹤0.01%	1631
2025 Q3	–	Sell	-3,600	Closed	-$1.6M	–	3509
2025 Q2	$1.6M	Buy	3,600 +1,600	+80%	+$737K	﹤0.01%	1849
2025 Q1	$970K	Buy	+2,000	New	+$932K	﹤0.01%	2001
2024 Q4	–	Sell	-500	Closed	-$233K	–	3305
2024 Q3	$233K	Sell	500 -400	-44%	-$192K	﹤0.01%	2523
2024 Q2	$422K	Buy	+900	New	+$391K	﹤0.01%	2124
2024 Q1	–	Sell	-800	Closed	-$326K	–	3163
2023 Q4	$326K	Buy	+800	New	+$296K	﹤0.01%	2124
2023 Q1	–	Sell	-16,800	Closed	-$4.85M	–	3195
2022 Q4	$4.85M	Hold	16,800	–	–	0.01%	1048
2022 Q3	$4.86M	Buy	16,800 +12,900	+331%	+$3.71M	0.01%	1013
2022 Q2	$1.1M	Buy	+3,900	New	+$1.04M	﹤0.01%	1711
2019 Q4	–	Sell	-30,000	Closed	-$5.08M	–	1518
2019 Q3	$5.08M	Buy	+30,000	New	+$5.31M	0.04%	543
2019 Q2	–	Sell	-81,000	Closed	-$14.9M	–	1750
2019 Q1	$14.9M	Buy	+81,000	New	+$15M	0.1%	291

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Balyasny Asset Management's VRTX Position: Q1 2026 in Review

Balyasny Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 65% in Q1 2026, selling an estimated $34.2M and leaving 40,137 shares worth $17.9M. The position accounts for 0.02% of the portfolio, ranked #733.

Balyasny Asset Management first reported a position in VRTX in Q2 2013 and has held it in 32 quarters since. The position peaked at $78.6M in Q1 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Balyasny Asset Management held 40,137 shares of Vertex Pharmaceuticals worth $17.9M as of Q1 2026.
Balyasny Asset Management sold 73,351 Vertex Pharmaceuticals shares in Q1 2026, an estimated $34.2M.
Vertex Pharmaceuticals made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #733 holding.
Balyasny Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 32 quarters since.
Balyasny Asset Management's Vertex Pharmaceuticals position peaked at $78.6M in Q1 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.